Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The Search for Next-Gen Expression Systems

Minakem’s facility in Belgium enhances capacity to scale production of highly potent ingredients for small to full GMP batches.

Minakem Opens New High Containment Facility

The company will provide the first FlexFactory manufacturing platform for cell therapy manufacturing.

GE Healthcare Equips China Cell Therapy Manufacturing Plant with FlexFactory

TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.

Lonza to Manufacture TxCell Product

Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.

Catalent to Develop Biosimilars for Valerius Biopharma

Naturally occurring and engineered albumins are being explored as a tool to enhance the stability of drugs, including biologics, and extend shelf-life.

Albumin Attachment Can Make Better Biobetters

The companies have extended a contract agreement for the commercial manufacture of the active pharmaceutical ingredient for vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.

Lonza, Proteon Therapeutics Extend API Manufacturing Partnership

The new platform is expected to speed up cell line development.

Sanofi Buys Berkeley Lights’ Cell Line Platform

Kemiex trading network is designed to increase safety in the sourcing of APIs and additives.

Platform Offers Online API Trading

The new 300,000-square-foot facility is considered the largest dedicated cell and gene therapy manufacturing facility with fully integrated services.

API Synthesis and Manufacturing, Large Molecule